292
The publishing house "Yuridychna Praktika" announced the twenty-first issue of Ukrainian Law Firms. A Handbook for Foreign Clients
213
We continue to inform our readers about the events of the annual XIII Congress "Pharmacies of the World-2024", which took place in Kyiv with the participation of more than 300 pharmaceutical professionals from all over Ukraine and abroad.
584
This year's WWL: Life Sciences once again recognized LA Law Firm managing partner among the leaders.
620
The pharmaceutical market is always in the focus of attention of the Antimonopoly Committee of Ukraine (AMCU) due to its social importance. A number of specific features of this market add additional challenges.
1158
According to the results of the recently published international study The Legal 500 Europe, Middle East & Africa 2024 LA Law Firm is recognized among the leading law firms of Ukraine.
843
LA Law Firm held a webinar "Regulatory changes for pharmaceutical sector in 2024. Conclusions and forecasts". During the event, the participants discussed changes in the Health Technology Assessment procedure, regulation of prices for medicines, the Prozorro Market Electronic Catalogue, regulatory plans to change approaches to the circulation of dietary supplements, etc.
1220
The national ranking features three partners and a counsel across four practice categories. Managing partner Dmytro Aleshko named among the TOP 100 legal practitioners in Ukraine and leaders in Medical Law / Pharmaceuticals.
1369
As soon as the pharmaceutical market began to recover from the adoption of the new List of OTC medicines prohibited for advertising, the Order of the Ministry of Health No. 1894 dated 02.11.2023 suspended its validity until 1 March 2024. In order to understand the legal implications of these developments, it is important to focus on certain aspects.
1023
On October 17, the MOH approved legislation requiring the international non-proprietary name of medicines to be indicated on paper and electronic prescriptions along with the mandatory indication of the form and dosage.
1487
The "Bolar Rule" is a provision that does not recognize as an infringement of a patent for an original medicinal product the actions taken by the applicant of a generic medicinal product (analogue of an original medicinal product) for the purpose of conducting trials and state registration of such medicinal product until the expiry of the patent.
